SuperGen mitomycin C oncologic reformulation is in final labeling discussions with FDA, firm says.
SUPERGEN MITOMYCIN C GENERIC ONCOLOGY DRUG IN FINAL LABELING discussions with FDA, and the company expects approval for the reformulation of mitomycin C later this spring or summer, Chief Financial Officer David Fineman announced at the Dillon Read conference May 7. The company filed the ANDA for mitomycin C in March 1995. The drug is used mostly for gastric and pancreatic cancers. During 1996, SuperGen expects filings to go to FDA for reformulated versions of etoposide, vincristine and cisplatin, Fineman noted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth